In vitro effects of Bifidobacterium lactis-based synbiotics on human faecal bacteria

Henrique-Bana, Fernanda Carla; Wang, Xuedan; Costa, Giselle Nobre; Spinosa, Wilma Aparecida; Miglioranza, Lucia H. S.; Scorletti, Eleonora; Calder, Philip C.; Byrne, Christopher D.; Gibson, Glenn R.

doi:10.1016/j.foodres.2019.108776

Cited by 14 publications

(7 citation statements)

References 50 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This property of B. lactis HN019™ may support tolerance for the fermentation of oligosaccharides in vivo , which is in line with clinical observations of B. lactis HN019™ on reduced flatulence ( 21 , 32 ). In addition, lactate and acetate are produced during B. lactis HN019™ fermentation, indicating potential roles in digestion of dietary components without differentiation of the origin; carbohydrate or protein ( 89 , 102 ).…”

Section: Assist Digestion and Utilization Of Macronutrientsmentioning

confidence: 99%

Bifidobacterium animalis subsp. lactis HN019 Effects on Gut Health: A Review

Cheng¹,

Laitila²,

Ouwehand³

2021

Front. Nutr.

View full text Add to dashboard Cite

Optimal gut motility is central to bowel function and gut health. The link between the gut dysmotility related disorders and dysfunctional-intestinal barriers has led to a hypothesis that certain probiotics could help in normalizing gut motility and maintain gut health. This review investigates the roles of Bifidobacterium animalis subsp. lactis HN019 (B. lactis HN019™) on gut health, and its mechanisms of action in various pre-clinical and clinical studies. Research supports the hypothesis that B. lactis HN019™ has a beneficial role in maintaining intestinal barrier function during gastrointestinal infections by competing and excluding potential pathogens via different mechanisms; maintaining normal tight junction function in vitro; and regulating host immune defense toward pathogens in both in vitro and human studies. This has been observed to lead to reduced incidence of diarrhea. Interestingly, B. lactis HN019™ also supports normal physiological function in immunosenescent elderly and competes and excludes potential pathogens. Furthermore, B. lactis HN019™ reduced intestinal transit time and increased bowel movement frequency in functional constipation, potentially by modulating gut–brain–microbiota axis, mainly via serotonin signaling pathway, through short chain fatty acids derived from microbial fermentation. B. lactis HN019™ is thus a probiotic that can contribute to relieving gut dysmotility related disorders.

show abstract

Section: Assist Digestion and Utilization Of Macronutrientsmentioning

confidence: 99%

Bifidobacterium animalis subsp. lactis HN019 Effects on Gut Health: A Review

Cheng¹,

Laitila²,

Ouwehand³

2021

Front. Nutr.

View full text Add to dashboard Cite

show abstract

“…Increased populations of bifidobacteria in gut microbiota should indicate high availability of carbohydrates susceptible for metabolization by these micro‐organisms (Henrique‐Bana et al . 2020).…”

Section: Discussionmentioning

confidence: 99%

“…2016; Henrique‐Bana et al . 2020). This statement is in agreement with the increased production of butyric acid found in media with digested AB and GB after 24 h of colonic fermentation.…”

Section: Discussionmentioning

confidence: 99%

Acerola ( Malpighia glabra L.) and guava ( Psidium guayaba L.) industrial processing by‐products stimulate probiotic Lactobacillus and Bifidobacterium growth and induce beneficial changes in colonic microbiota

et al. 2020

View full text Add to dashboard Cite

Aims This study evaluated whether by‐products from industrial processing of acerola (Malpighia glabra L.; AB) and guava (Psidium guajava L.; GB) fruit may stimulate the growth and metabolism of probiotic Lactobacillus and Bifidobacterium and induce changes in human colonic microbiota. Methods and Results The ability of non‐digested and digested AB or GB to stimulate the growth ad metabolism of Lactobacillus acidophilus LA‐05, Lactobacillus casei L‐26 and Bifidobacterium animalis subsp. lactis BB‐12 was evaluated. Changes in populations of distinct bacterial groups of human colonic microbiota induced by digested AB and GB were evaluated using an in vitro colonic fermentation system. Non‐digested and digested AB and GB favoured probiotic growth. No difference among counts of probiotics in media with glucose, fructooligosaccharides and non‐digested and digested AB and GB was found during a 48‐h cultivation. Cultivation of probiotics in media with non‐digested and digested AB and GB resulted in decreased pH, increased organic acid production and sugar consumption over time. Digested AB and GB caused overall beneficial changes in abundance of Bifidobacterium spp., Lactobacillus–Enterococcus, Eubacterium rectall–Clostridium coccoides and Bacteroides–Provotella populations, besides to decrease the pH and increase the short‐chain fatty acid production during a 24‐h in vitro colonic fermentation. Conclusion AB and GB could be novel prebiotic ingredients because they can stimulate the growth and metabolism of probiotics and induce overall beneficial changes in human colonic microbiota. Significance and Impact of the Study AB and GB stimulated the growth and metabolism of probiotics, in addition to induce beneficial alterations in human colonic microbiota composition and increase short‐chain fatty acid production. These results characterize AB and GB as potential prebiotic ingredients and fruit processing by‐products as sources of added‐value compounds.

show abstract

“…The short-chain fatty acid (SCFAs) levels in various groups of fermentation broth were determined by gas-phase method according to the protocol described by Henrique-Bana et al with appropriate modifications ( 20 ). Briefly, 0.5 mL of 10% fecal suspension was mixed with 0.1 mL of 25% metaphosphoric acid for 24 h at −20°C.…”

Section: Methodsmentioning

confidence: 99%

In vitro Study of Bifidobacterium lactis BL-99 With Fructooligosaccharide Synbiotics Effected on the Intestinal Microbiota

Zhang

Zhao

et al. 2022

Front. Nutr.

View full text Add to dashboard Cite

Probiotics and prebiotics relieve constipation by altering the composition of the intestinal microbiota. However, their synergistic mechanism of action remains unclear. Herein, an in vitro fermentation model was constructed to examine the synergistic effects of Bifidobacterium lactis BL-99 and fructooligosaccharide (FOS) on the regulation of intestinal microbiota from a population with constipation. The utilization of FOS was promoted by BL-99, and the increase rate being 22.33%. Relative to the BL-99 and the FOS groups, the BL-99_FOS group showed a highly significant increase in acetic acid content (P < 0.01) and a marked decrease in CO2 and H2S contents (P < 0.01) in the fermentation broth. In addition, the BL-99_FOS combination significantly changed the structure of the intestinal microbiota, enhanced the relative abundances of beneficial bacteria that relieved constipation, including Bifidobacterium, Fecalibacterium, Lactobacillus, Subdoligranulum, and Blautia, and decreased those of the harmful bacteria, including Bilophila and Escherichia-Shigella. These findings suggested that BL-99 and FOS synergistically regulated the composition and structure of the intestinal microbiota from the population with constipation and increased acetic acid and decreased CO2 and H2S levels, thereby providing a theoretical basis for the application of synbiotics.

show abstract

In vitro effects of Bifidobacterium lactis-based synbiotics on human faecal bacteria

Abstract: In vitro effects of Bifidobacterium lactis-based synbiotics on human faecal bacteria.

Cited by 14 publications

References 50 publications

Bifidobacterium animalis subsp. lactis HN019 Effects on Gut Health: A Review

Bifidobacterium animalis subsp. lactis HN019 Effects on Gut Health: A Review

Acerola ( Malpighia glabra L.) and guava ( Psidium guayaba L.) industrial processing by‐products stimulate probiotic Lactobacillus and Bifidobacterium growth and induce beneficial changes in colonic microbiota

In vitro Study of Bifidobacterium lactis BL-99 With Fructooligosaccharide Synbiotics Effected on the Intestinal Microbiota

Contact Info

Product

Resources

About